Clinical Trial

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

Study acronym: H06_04TP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The current study is a follow-up to 2 previous parent studies, a dose-selection study with 3 different dose-levels of the altSonflex1-2-3 vaccine in a schedule of 3 vaccinations (H06\_01TP study \[NCT05073003, 212149\]) and a study with an alternate 2 vaccination schedule H06\_02TP study \[NCT06663436, 219449\]). The current study aims to assess the longevity of the immune response to the selected dose of the altSonflex1-2-3 vaccine 1, 2, and 3 years after the last vaccination in African children. The study involves no new vaccinations but will collect immunogenicity blood samples from participants.
Trial Details
NCT Number NCT07320716
Lead Sponsor GlaxoSmithKline
Conditions Diarrhoea
Enrollment 528 participants
Start Date 2026-01-02
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-06